Communications
DOI: 10.1002/anie.200804804
Antimicrobial Photochemistry
Exploiting a Bacterial Drug-Resistance Mechanism: A Light-Activated
Construct for the Destruction of MRSA**
Xiang Zheng, Ulysses W. Sallum, Sarika Verma, Humra Athar, Conor L. Evans, and
Tayyaba Hasan*
The prevalence of bacterial drug resistance makes it imper-
ative to develop new targeted strategies that can be used
either as monotherapies or in conjunction with existing
antibiotic regimens. Photodynamic therapy (PDT) has such
potential. PDT is a photochemistry-based emerging technol-
ogy that relies on the wavelength-specific light activation of
certain nontoxic chemicals (photosensitizers, PSs) to form
active molecular species (AMSs) that are toxic to surrounding
biological targets.[1] The reported effectiveness of PDTagainst
pathogens in general, and methicillin-resistant Staphylococ-
cus aureus (MRSA) in particular,[2] makes it a potentially
powerful technology for the treatment of drug-resistant
infections. AMSs have multiple cellular targets, in contrast
to conventional antibiotics, such as b-lactams and amino-
glycocides,[3] which inhibit the activity of single enzymes. This
multifaceted nature of PDT action has the advantage that it
decreases the probability of generating PDT-resistant strains
of bacteria; however, this feature can also be a limitation,
owing to nonspecific PS accumulation, which results in
damage to healthy host tissue.[4]
The aim of this study was to exploit a bacterial drug-
resistance mechanism to activate the PS locally, only at the
site of infection, for a more specific PDT effect. The strategy
involves the synthesis of a construct which can be activated by
light and which recognizes a molecular target that is unique to
the bacterium of interest. The advantage of this approach is
that it enables much-enhanced selectivity, as the construct can
only be activated by light after interaction with the molecular
target. The construct can not be activated at any other site.
This enhanced selectivity could enable the use of PDT more
broadly for regional infections than is currently possible; at
present, PDT can only be used for highly localized infections.
This study focuses on the b-lactamase enzyme as the
molecular target. One way in which bacteria resist the
action of b-lactam antibiotics is through the production of
b-lactamase, which cleaves the b-lactam ring hydrolytically.[5]
In the case of cephalosporins, ring opening of the b-lactam is
accompanied by the release of the substituent at the 3’-
position. Zlokarnik et al. used this feature to design b-
lactamase reporter systems to detect gene-promoter activa-
tion in mammalian cells.[6,7]
In this study, we targeted the b-lactamase expressed by
MRSA. In designing the molecular construct (b-lactamase-
enzyme-activated photosensitizer, b-LEAP), we took advant-
age of the photophysical phenomenon known as quenching.
PSs can be quenched when in close proximity to each other.
As a result, the probability of a PS excited-state transition is
diminished, which leads to decreased fluorescence or AMS
formation. b-LEAP is designed in such a way that, upon
cleavage by b-lactamase (Scheme 1), the PS is released from
homodimeric, ground-state quenching to yield an enzyme-
specific, light-activated antimicrobial action. The b-lacta-
mases were ideal targets for this proof-of-principle study
owing to the prevalence of b-lactamase expression among
bacteria and its high enzymatic efficiency.[8,9]
The PS 5-(4’-carboxybutylamino)-9-diethylaminoben-
zo[a]phenothiazinium chloride (EtNBS-COOH), an EtNBS
derivative, was demonstrated previously to be a potent
antimicrobial agent.[10] In the current study, the free terminal
carboxy group of the PS was conjugated to a cephalosporin
derivative, 7-amino-3-chloromethyl-3-cephem-4-carboxylic
acid p-methoxybenzyl ester (ACLE), which contains a b-
lactam ring. Thus, ACLE was modified with two primary
amino groups and treated with EtNBS-COOH (Scheme 2).
The final product 3 (b-LEAP) was purified and characterized
by HPLC, mass spectrometry, and NMR spectroscopy (see
Figures 1 and 3 in the Supporting Information). b-LEAP
showed a nearly fivefold decrease in fluorescence emission
(excitation at 625 nm) relative to EtNBS-COOH (Figure 1).
This result indicates the quenching effect of the two PS
moieties in the molecule. There are two mechanisms of PS
quenching: 1) static (ground-state) quenching, such as fluo-
rophore homo- or heterodimerization, and 2) dynamic
(excited-state) quenching through Fꢀrster resonance energy
transfer (FRET). The distortion of the long-wavelength
absorption peak of b-LEAP (with an extra shoulder that is
blue-shifted from the maximum absorption peak by 30 nm)
with respect to that of EtNBS-COOH (see Figure 2 in the
Supporting Information) suggested a ground-state quenching
mechanism.[11] The short separation (ca. 2.4 nm) of the two PS
moieties assured a high quenching efficiency. Homodimeri-
[*] Dr. X. Zheng,[+] U. W. Sallum,[+] S. Verma, H. Athar, C. L. Evans,
Prof. T. Hasan
Wellman Center for Photomedicine
Harvard Medical School and Massachusetts General Hospital
40 Blossom Street, Boston, MA 02114 (USA)
Fax: (+1)617-726-8566
E-mail: thasan@partners.org
n.asp
[+] X. Zheng and U. W. Sallum contributed equally to this work.
[**] We thank Otsuka Chemicals for their generous gift of ACLE and Dr.
Robert Moellering, Jr. for kindly providing the strains of MRSA. This
research was funded by the Department of Defense/Air Force Office
of Scientific Research (DOD/AFOSR) (grant number: FA9550-04-1-
0079). MRSA=methicillin-resistant Staphylococcus aureus.
Supporting information for this article is available on the WWW
2148
ꢀ 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Angew. Chem. Int. Ed. 2009, 48, 2148 –2151